RxDoctor Payments Data

James Braxton Little

Podiatrist · Pacific Palisades, CANPI 1992866412

Payments from drug & device makers

$798in general payments, 2019–2025

Across 31 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dynasplint Systems Inc.$178
  • Keswick Pharmaceuticals LLC$145
  • Smith+Nephew$133
  • Polynovo North America LLC$66
  • Paratek Pharmaceuticals, Inc.$33
  • Biotissue Holdings Inc.$30
  • plus $214 from 10 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 50th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$108,287
Medicare patients
462
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole14$16,603
Ciclopirox68$1,851
Clotrimazole32$1,395
Ketoconazole29$777
Gabapentin11$478
Terbinafine Hcl24$446
Fluconazole11$175
Cephalexin18$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$20$16,60314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 721 podiatrist providers in California.

Other podiatrist in Pacific Palisades

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →